ImmunoPrecise Antibodies Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ImmunoPrecise Antibodies Ltd. generated cash of -$4,246,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,021,000 last year. Net change in cash is therefore -$4,821,000.
Cash Flow
| 2014 | -36.10K | -600 | -600 |
|---|---|---|---|
| 2016 | 284.08K | -81.58K | -91.90K |
| 2017 | -721.65K | -174.61K | 3.16M |
| 2018 | -3.41M | -7.17M | 9.80M |
| 2019 | -3.20M | -2.20M | 9.35M |
| 2020 | -1.39M | -1.58M | 174.70K |
| 2021 | -600K | -2.45M | 43.37M |
| 2022 | -9.92M | -5.20M | 2.88M |
| 2023 | -19.83M | -1.96M | -621K |
| 2024 | -4.24M | -1.56M | 1.02M |
IPA Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2020 | 2019 | 2019 | 2017 | 2017 | 2015 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.36M | 30.04M | 41.83M | 2.69M | 5.53M | 1.80M | 2.57M | 340.88K | 213.24K | 40.55K |
Operating activities | ||||||||||
Net income | -27.17M | -26.56M | -16.70M | -7.34M | -4.94M | -7.61M | -5.17M | -5.38M | 151.03K | -62.31K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 5.73M | 6.68M | 3.76M | 3.71M | 3.40M | 2.26M | 458.07K | 50.60K | 41.88K | 1.04K |
Stock-based compensation expense | 1.53M | 1.94M | 3.08M | 2.74M | 739K | 1.11M | 1.22M | 198.03K | 0 | 0 |
| Deferred income tax benefit | 1.53M | 1.94M | 3.08M | 2.74M | 739K | 1.11M | 1.22M | 198.03K | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -601K | -561K | 163K | -439K | -933.28K | 102.11K | -284.95K | -46.80K | -74.89K | -146.68K |
Inventories | -102K | -185K | -501K | -316K | -23.39K | 289.52K | -27.94K | -58.49K | 0 | 0 |
Accounts payable | 0 | -1.55M | 781K | -73K | 171.99K | -421.67K | 482.99K | 592.85K | 0 | 0 |
Cash generated by operating activities | -4.24M | -19.83M | -9.92M | -600K | -1.39M | -3.20M | -3.41M | -721.65K | 284.08K | -36.10K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -214.14K | 0 | 0 |
Investments In Property Plant And Equipment | -1.39M | -1.49M | -1.25M | -1.42M | -575.64K | -645.05K | -345.48K | -530.75K | -17.48K | -20.31K |
Acquisitions Net | -146K | -592K | -3.69M | -1.02M | -1.00M | -1.55M | -6.82M | 141.99K | 0 | 0 |
Cash generated by investing activities | -1.56M | -1.96M | -5.20M | -2.45M | -1.58M | -2.20M | -7.17M | -174.61K | -81.58K | -600 |
Financing activities | ||||||||||
Common Stock Issued | 2.36M | 716K | 3.85M | 44.15M | 493.17K | 9.84M | 5.59M | 4.31M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -90K | -65K | -200K |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -1.33M | -1.33M | -962K | -2.97M | -915.07K | -202.68K | -6.12K | 97.5K | -26.90K | -50K |
Cash used in financing activities | 1.02M | -621K | 2.88M | 43.37M | 174.70K | 9.35M | 9.80M | 3.16M | -91.90K | -600 |
Net Change In Cash | -4.82M | -21.68M | -11.79M | 39.14M | -2.84M | 3.73M | -772.31K | 2.23M | 127.63K | -36.70K |
Cash at end of period | 3.54M | 8.36M | 30.04M | 41.83M | 2.69M | 5.53M | 1.80M | 2.57M | 340.88K | 3.85K |
| Data source | Data source | Data source |